hotspot -WSS

hotspot

author：entertainment 2025-09-30 12:16:52 - browse：42

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Chemotherapy shortages won’t get better under Biden’s latest plan

WSS

What PEPFAR has meant on the ground in Ukraine

Medical school prerequisites are outdated

Pharma patents targeted by Biden in move to slash drug prices

Ventyx halts psoriasis drug development after lackluster trial results

Medicare’s new pay boost for primary care is angering specialists

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

hotspot

hotspot

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA needs staff influx to meet gene therapy needs, Marks says

Tori Bowie and the unacceptable rates of Black maternal death

FDA reorg will put new emphasis on investigations, sources say

23andMe had bad news about my health. I wish a person had delivered it

In diabetes hearing, Sanders takes on a new foe: food makers

After affirmative action ruling, medical educators look to 'holistic review'

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Trump demands the U.S. pay no more for drugs than other countries … again

Why sickle cell disease is getting the first CRISPR treatment

focus

STAT letters to the editor on burnt

FDA needs staff influx to meet gene therapy needs, Marks says

After sickle

Chemotherapy shortages won’t get better under Biden’s latest plan

What PEPFAR has meant on the ground in Ukraine

SCOTUS to consider access to abortion pill mifepristone

leisure time

entertainment

hotspot

hotspot